focus -WSS

focus

author：comprehensive 2025-10-02 10:45:14 - browse：3

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

explore

Wikipedia

WSS

Finland to offer bird flu vaccine to select groups of people, a possible global first

Illumina board agrees to spin off Grail, as divestment plans proceed

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

FTC loses bid to block Novant's North Carolina hospital merger

Illumina board agrees to spin off Grail, as divestment plans proceed

BD to buy Edwards patient monitoring unit for $4.2 billion

Wikipedia

focus

hotspot

Medical leaders decry Supreme Court decision on affirmative action

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What would happen to your eyes if you looked at the solar eclipse?

New air purifier tech could be key to improving indoor air quality

A new initiative will help leaders fight the next pandemic

Drug repurposing or repositioning? The language matters

STAT wants to know your pick for a great summer read or listen

Psychedelics group wrestles with new pharma identity

In areas with more Black doctors, Black people live longer

leisure time

3 hurdles to bringing medical devices to the U.S. market

An outdated Medicare rule harms dementia patients with anxiety

Data don't support strong claims for Covid

CMS got Medicare Advantage quality rating wrong, judge rules

Why drug prescriptions should include diagnoses

Cloning humans is technically possible. It's curious no one has tried

explore

Wikipedia

leisure time

hotspot